Arcturus BioCloud's genome splicing robot. It’s long been the case that life sciences investors don’t get the attention that their more traditional tech counterparts do. They’re underrepresented on lists of top investors in venture capital. They’re also remarkably underfunded, according to institutional investors (or limited partners) who back venture firms. It’s the “life sciences guys who are smart… Read More

Source: News